Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19
Fecha
2020Autor
Liu, Chenglong
Zhu, Di
Documentos PDF
Resumen
The outbreak of pneumonia caused by a new coronavirus (SARS-CoV-2)
occurred in December 2019, and spread rapidly throughout the world. There have been
other severe coronavirus outbreaks worldwide, namely, severe acute respiratory
syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV). Because
the genetic diversity of coronaviruses renders the design of vaccines complicated,
broad spectrum-anti-coronavirus drugs have become a critical approach to control the
coronavirus epidemic. Cyclophilin A is an important protein needed for coronavirus
replication, and its inhibitor cyclosporine has the ability to suppress coronavirus on a
broad spectrum. CD147-S protein was found to be one route by which SARS-CoV-2
invades host cells, while CD147 was found to play a functional role in facilitating the
infection of host cells by SARS-CoV. The CyPA/CD147 interaction may play a critical
role in the ability of the SARS-CoV-2 virus to enter the host cells. However, cyclosporine
A has immunosuppressive effects, so the conditions for its use as an antiviral drug are
limited. As a result, cyclosporine A analogues without immunosuppressive side effects
have attracted lots of interest. This review primarily discusses the drug development
prospects of cyclophilin A as a therapeutic target for the treatment of coronavirus
infection, especially coronavirus disease 2019 (COVID-19), and nonimmunosuppressive cyclosporine analogues.
Palabras clave
Ayclophilin a; Cyclosporine A; COVID-2019; SARS-CoV2Enlace al recurso
https://doi.org/10.1016/j.medidd.2020.100056Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.